Profile: Biocryst Pharmaceuticals, Inc. designs, optimizes and develops novel, small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. We use structure-based drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most effectively discover and develop new therapeutic small molecule pharmaceuticals. Our therapeutic product pipeline contains two advanced clinical programs such as neuraminidase inhibition and purine nucleoside phosphorylase inhibition.

The company has revenues of USD 50-100 Million, has ~80 employees. NASDAQ:BCRX (SEC Filings)